Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells

Carfilzomib (CFZ) is a second-generation proteasome inhibitor that is Food and Drug Administration and European Commission approved for the treatment of relapsed or refractory multiple myeloma. CFZ is an epoxomicin derivative with an epoxyketone electrophilic warhead that irreversibly adducts the ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cell Proteomics
Main Authors: Federspiel, Joel D., Codreanu, Simona G., Goyal, Sandeep, Albertolle, Matthew E., Lowe, Eric, Teague, Juli, Wong, Hansen, Guengerich, F. Peter, Liebler, Daniel C.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society for Biochemistry and Molecular Biology 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5054346/
https://ncbi.nlm.nih.gov/pubmed/27503896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/mcp.M116.059709
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados